BLS Successfully Presents Cervical Precancer Treatment Drug ‘BLS-M07’ at International Conference

Confirmed Applicability for Low Survival Rate Advanced Cervical Cancer
Aiming for Commercialization Alongside Indication Expansion

[Asia Economy Reporter Kwangho Lee] BL, a new drug development specialist company (formerly BioLeaders), announced on the 6th that it successfully presented the research results of its cervical intraepithelial neoplasia treatment drug candidate ‘BLS-M07’ at the ‘International Gynecologic Oncology Society Annual International Meeting’ held last week.

The conference, held in New York from the 29th of last month to the 1st (local time), was attended by global gynecologic oncology specialists and pharmaceutical industry representatives, who simultaneously conducted face-to-face and online presentations on the latest research trends and drug development achievements in the field of gynecologic oncology.

BL presented the research results of its clinical development drug BLS-M07 through Professor Jaegwan Lee, head of clinical trials and a gynecology professor at Korea University College of Medicine. Based on the research results of BLS-M07 at this conference, the company explored the possibility of expanding its indication to cervical cancer during meetings with pharmaceutical licensing officials and oncology experts.

According to experts, for patients with advanced cervical cancer who are currently inoperable, chemotherapy or radiation therapy is administered; however, due to low response rates and high side effects, there is a high demand for new treatments. In particular, immune checkpoint inhibitors, known as the latest anticancer drugs, have low efficacy when used alone, making the development of new combination therapies urgently needed.

BLS-M07 is an oral therapeutic vaccine targeting human papillomavirus (HPV), known as a major cause of cervical infection and cancer. When taken orally, it induces mucosal immune responses in the intestines, forming HPV antibodies and stimulating T cells to eliminate infected cells within the cervix. Therefore, many experts have expressed positive opinions that combining it with immune checkpoint inhibitors, which induce T cell activity, would have a strong synergistic effect.

This drug is based on human-friendly lactic acid bacteria and has been evaluated as a safe substance with no severe drug-related side effects through previous clinical trials. Recently, the IND review for phase 2/3 clinical trials was approved by the Ministry of Food and Drug Safety, and preparations for patient recruitment have begun at five medical institutions.

A BL official stated, “At this conference, we were able to confirm the therapeutic efficacy of BLS-M07 for cervical intraepithelial neoplasia and, through discussions with oncology specialists, the potential application for advanced cervical cancer with low survival rates.” He added, “We will actively pursue the development of treatments for terminal cervical cancer patients, who currently have no breakthrough therapies, by combining with immune checkpoint inhibitors, which we expect will increase the possibility of indication expansion and commercialization.”

This content was produced with the assistance of AI translation services.